Tactile Systems Q2 revenue up 9%, slightly beats estimates
TCMD•Outlook
The company now sees 2026 revenue at $360 million to $366 million, down from $360 million to $368 million.
It maintained 2026 adjusted EBITDA guidance at $49 million to $51 million.
The revised outlook reflects confidence in the lymphedema line, but a cautious view on airway clearance sales.
Quarterly results
Tactile Systems said second-quarter revenue rose 9%, slightly beating analyst expectations.
Adjusted EBITDA for the quarter also beat analyst expectations. The company repurchased $5.3 million of stock during the quarter.
Revenue drivers and margin
Revenue growth was driven by a 12% increase in sales and rentals of the lymphedema product line.
Airway clearance product sales fell 7% due to temporary inventory management dynamics linked to the launch of the next-generation AffloVest system.
Gross margin rose to 76% from 75% due to continued operating execution and product cost discipline.
